FBT News and Press, First Trust Amex Biotech Index Fund From 06/08/23

2023-06-08 23:17:09 ET Summary The Health Care Select Sector SPDR ETF and the Vanguard Health Care ETF are the two most popular Health Care ETFs, with a combined $57 billion in assets under management. Both ETFs have a 0.10% expense ratio, a five-year beta around 0.70, and trade a...

2023-05-31 05:18:05 ET Summary Most stocks in FBT’s biotechnology portfolio beat returns of S&P 500 during the past one year. FBT also registered a price growth of 15.5 percent. However, over the past five months, return has been much lower than S&P 500, and price g...

2023-05-18 03:36:47 ET Summary Several ETFs exist offering investors concentrated biotech exposure that varies in stock selection and weighting schemes. While all of the choices exhibit 90%+ exposure to biotech stocks, only XBI is a true pure-play at nearly 100%. The low relat...

2023-05-17 00:15:00 ET Summary One of the most promising applications of AI in drug discovery is in the identification of new drug targets (AI can be used to discover new drugs). The ability to analyze large amounts of molecular and genomic data quickly and efficiently is somethin...

2023-05-17 00:00:00 ET Summary Markets are being shaped by disparate trends from falling energy prices to rising interest rates. During first-quarter earnings season, company reports indicated that these crosscurrents are intensifying business challenges—and making it harde...

2023-05-16 14:35:00 ET Summary Both the Consumer Price Index and Producer Price Index data for April confirmed that the strong but lumpy disinflationary trend continues. The US is now at a point where the Fed funds rate exceeds inflation. Historically that has signaled the end of ...

2023-05-02 01:25:00 ET Summary Interest rates continue to drive markets, with central banks walking a fine line between taming inflation and avoiding recession. The Fed isn’t quite finished with the tightening cycle yet, even as the market remains optimistic that rates will...

2023-04-17 10:30:00 ET Summary The joint stock-bond rally this year has put renewed focus on portfolio construction approaches. We think a new macro regime needs a new approach. U.S. stocks rose last week but lost steam on Friday on the market partly pricing out potential rate cut...

2023-04-12 02:26:28 ET Summary The White House's announcement on drug price caps caused a significant drop in biopharma stocks during Q1 2023. The impact of drug pricing-related caps and pressure will likely be limited, and the industry is expected to adapt and find new revenue st...

2023-03-24 03:00:00 ET Summary We remain selective in taking risk as macro factors continue to drive sentiment. Despite the uncertainties, investors should not lose sight of equities’ enduring role in a well-balanced portfolio. We advocate a near-term focus on resilienc...